List of Studies ( Metabolite:CMPciliatine)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Analysis Type |
|---|---|---|---|---|---|---|---|
| ST004291 | AN007136 | Metabolomics analysis of Plasmodium falciparum asexual-stage parasites treated with plasmepsin V peptidomimetics - 16 hour treatment | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST004290 | AN007134 | Metabolomics characterisation of Plasmodium falciparum response to plasmepsin V peptidomimetic inhibitors - 5 hour treatment | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST004274 | AN007113 | Loss of vitamin C biosynthesis protects from the pathology of a Schistosome infection and egg production. | Whole worm lysate | Worm | Schistosomiasis | University of Texas Southwestern Medical Center at Dallas | LC-MS |
| ST004207 | AN006997 | Tumour sampling conditions perturb the metabolic landscape of clear cell renal cell carcinoma | Kidney | Human, Mouse | Cancer | University of Cambridge | LC-MS |
| ST004194 | AN006966 | PfK13-associated artemisinin resistance slows drug activation and enhances antioxidant defence, which can be overcome with sulforaphane | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST004144 | AN006869 | Metabolic rewiring in isogenic SW48 colorectal cancer cells with different oncogenic KRAS G12 point mutations | Cultured cells | Human | Cancer | Brunel University of London | LC-MS |
| ST003712 | AN006092 | ndufs2-/- mitochondrial Leigh syndrome zebrafish model has shortened lifespan, morphologic anomalies, and altered one-carbon metabolism | Larvae | Zebrafish | Mitochondrial disease | Children's Hospital of Philadelphia | LC-MS |
| ST003565 | AN005857 | Metaboloomics analysis of the antimalarial compound WEHI-1888504 (aka compound 59) in Plasmodium falciparum (3D7) infected red blood cells | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST003340 | AN005474 | Effect of feeding and the mTORC1 activity on metabolism in Caenorhabditis elegans | Worms | C. elegans | Hiroshima University | LC-MS | |
| ST003179 | AN005221 | Property and Activity Refinement of Dihydroquinazolinone-3-carboxamides as Orally Efficacious Antimalarials that Target PfATP4 | Plasmodium cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST003160 | AN005184 | New class of heterospirocyclic compounds present strong and rapid activity against artemisinin- and multidrug-resistant P. falciparum parasites | Plasmodium cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST003144 | AN005160 | On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST002926 | AN004799 | Multi-“omics” analysis reveals the orphan P. falciparum protein kinase PfPK8 regulates multi-gene family expression | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST002792 | AN004543 | Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as a cross-species strategy to treat malaria | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST002477 | AN004046 | Neutrophil metabolomics in COVID-19 | Neutrophils | Human | COVID-19 | UT Southwestern Medical Center | LC-MS |
| ST002371 | AN003866 | High-resolution metabolomics analysis of NLRP3 inflammasome activated macrophages | Macrophages | Mouse | Inflammation | Wake Forest School of Medicine | GC-MS |
| ST002309 | AN003772 | Targeting malaria parasites with novel derivatives of azithromycin | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST002108 | AN003449 | Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 3) | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST002107 | AN003446 | Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 2) | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST002106 | AN003445 | Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 1) | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001788 | AN002900 | β-Adrenergic regulation of metabolism in macrophages (part-IV) | Macrophages | Human | Monash University | LC-MS | |
| ST001611 | AN002645 | Mouse model of sarcoma (STS) to characterize tumor vulnerabilities and identify novel targets for anti-cancer treatment | Muscle | Mouse | Cancer | North Carolina State University | LC-MS |
| ST001611 | AN002645 | Mouse model of sarcoma (STS) to characterize tumor vulnerabilities and identify novel targets for anti-cancer treatment | Sarcoma | Mouse | Cancer | North Carolina State University | LC-MS |
| ST001547 | AN002577 | β-Adrenergic regulation of metabolism in macrophages | Macrophages | Human | Monash University | LC-MS | |
| ST001315 | AN002190 | Retargeting azithromycin-like compounds as antimalarials with dual modality | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001276 | AN002117 | Development and Characterisation of a Novel Class of Aroyl Guanidine Containing Anti-Trypanosomal Compounds | Cultured cells | Trypanosoma brucei | Sleeping sickness | Monash University | LC-MS |
| ST001205 | AN002007 | Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites | Cultured cells | Human | Malaria | Monash University | LC-MS |
| ST001205 | AN002007 | Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001202 | AN002001 | Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites | Cultured cells | Human | Malaria | Monash University | LC-MS |
| ST001202 | AN002001 | Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001201 | AN001999 | Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites | Cultured cells | Human | Malaria | Monash University | LC-MS |
| ST001201 | AN001999 | Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001188 | AN001980 | P. falciparum infected erythrocytes | Cultured cells | Plasmodium falciparum | Malaria | University of Melbourne | LC-MS |
| ST001175 | AN001951 | Multi-omics analysis demonstrates unique mode of action of a potent new antimalarial compound, JPC-3210, against Plasmodium falciparum | Plasmodium cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001033 | AN001694 | Determination of mode of action of anti-malalrial drugs using untargeted metabolomics | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST000546 | AN000833 | Multi-omics based identification of specific biochemical changes associated with PfKelch13-mutant artemisinin resistant Plasmodium | Cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST000539 | AN000818 | Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes (part II) | Cells | Human | Monash University | LC-MS | |
| ST000403 | AN000642 | Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes | Cells | Human | Monash Institute of Pharmaceutical Sciences | LC-MS |
